CDH1 and prostate carcinoma: Therapy‐induced selection of cells with EMT characteristics, eventually displaying gain of ZEB1 and VIM, but repressed CDH1, MIR200C and MIR205 expression, was observed in vitro after long‐term exposures to gemcitabine in BxPC3 pancreatic cancer cells and to Docetaxel in PC3 and DU‐145 prostate cancer cells (Wellner et al, 2009; Puhr et al, 2012).